The Center for Integrated Diagnostics (CID) mission is to work across Massachusetts General Hospital to foster development of clinical actionable diagnostics and accelerate the adoption of personalized medicine. While we have made strides in the cancer field it is our goal to expand our testing to other disciplines.

Genotyping Tumors & Targeted Therapies  

The primary role of the CID is to genotypically fingerprint patient tumors across the complete spectrum of disease sites in an effort to direct molecularly-targeted therapies, thereby enhancing the efficacy of drug treatment offerings as well as supporting prospective clinical trial designs. Patient analyses are performed as CLIA-certified clinical tests and results are generated within a timeframe that allows for direct patient care decision making as well as providing the opportunity for patients whose cancers harbor susceptible genotypes to be offered the most appropriate clinical treatment. In addition, our laboratory pursues retrospective and corollary research studies to support the expansion of our genotyping profiles. To accomplish these goals, the lab utilizes a number of molecular and cellular techniques, including fluorescent in situ hybridization (FISH), qPCR, DNA sequencing, SNP-based approaches and DNA sizing analyses. The combination of these approaches allows for the detection of somatic genetic aberrations on multiple levels, including gene copy number, point mutations and small deletions and insertions. 

Molecular Diagnostics & Mass General Pathology

In 2005, Mass General's department of Pathology created the Molecular Diagnostics Laboratory under the direction of Dr. A. John Iafrate, MD, PhD.  The test offerings started out small; the original two tests were 1P19Q fluorescent in situ hybridization (FISH) and microsatellite instability (MSI).  The menu of tests has expanded significantly over time with the key addition of ALK FISH which functions to assist in lung cancer treatment. In 2008, Dr. Iafrate created the Translational Research Lab (TRL) in collaboration with Mass General Cancer Center. The TRL’s mission was to design a multiplex test that would simultaneously test for the top cancer mutations for all cancer types.  The resulting SNaPshot panel tests for 92 commonly mutated loci across 23 cancer genes.  In 2011, clinical molecular diagnostics was unified as the Center for Integrated Diagnostics (CID) at Mass General. In 2013 the CID rolled out its first next generation sequencing (NGS) assay, AMP translocation, which looks for gene rearrangement of ALK, ROS, and RET.  Building on past experience of targeting a specific number of genes in the original SNaPshot Panel and the NGS based technology of the AMP assay, we launched NGS Snapshot in 2014. The current version of this assay assesses single nucleotide variants and insertions/deletions in 104 known cancer genes, allowing us to provide the most comprehensive clinical assay for actionable cancer genes to date. The laboratory has since continued to expand its NGS assay menu, and now offers comprehensive NGS assays for solid tumors, heme malignancies, and sarcomas.

Licensure and Accreditations

The Center for Integrated Diagnostics has CLIA (Clinical Laboratory Improvement Amendments) certification through CMS (Centers of Medicare and Medicaid Services), and is accredited by the Joint Commission. Please see the Pathology Department Regulatory Compliance website to request a copy of the CLIA certificate.

The Center for Integrated Diagnostics is also a New York State CLEP (Clinical Laboratory Evaluation Program) licensed molecular laboratory for performing ROS1 FISH and gene translocation assays, which can generate critical information for treating lung cancer patients. For more information about these assays, please contact the laboratory at the phone numbers listed below.

Contact Information 

Center for Integrated Diagnostics (CID)

Jackson Building, 10th Floor

55 Fruit StreetBoston, MA 02114

  • Phone: 617-643-2716
  • Fax: 617-643-1623
  • For Billing, Specimen Submission, and Testing Status Questions : 617-724-1285


  • Monday through Friday, 8:30am to 5:00pm

Mailing Address

Massachusetts General Hospital
Center for Integrated Diagnostics (CID) 
Jackson Building, Floor 10
Mailstop: GRJ 1015
55 Fruit Street
Boston, MA 02114